纳武利尤单抗治疗复发性高级别胶质瘤的回顾性研究
该回顾性研究分析了本院50例复发性高级别胶质瘤患者接受纳武利尤单抗治疗的情况,主要终点为无进展生存期和总生存期。结果显示中位无进展生存期4.3个月(95%CI 3.5-5.3),中位总生存期6.5个月(95%CI 6.0-8.8),安全性可控,部分患者达疾病稳定。
要点
- 50例复发性高级别胶质瘤患者接受纳武利尤单抗,中位PFS 4.3个月,中位OS 6.5个月。
- 36例(72%)患者在2个月评估时达疾病稳定,中位稳定持续时间4.3个月。
- 4例(8%)发生3-4级不良事件,最常见为疲乏(16%)和便秘(10%)。
核心结论
- 纳武利尤单抗治疗与可控的安全性相关,在部分经重度预治疗的复发性高级别胶质瘤患者中观察到疾病稳定。
研究设计与样本
- 回顾性分析本院接受纳武利尤单抗治疗的高级别胶质瘤患者,纳武利尤单抗3 mg/kg每2周直至确认进展、不可耐受毒性、死亡或医生决定,每8周进行影像学评估。
主要发现
- 2015年4月至2017年10月共50例高级别胶质瘤患者接受纳武利尤单抗,其中43例联合贝伐珠单抗,44例为贝伐珠单抗难治,7例接受纳武利尤单抗单药治疗,所有患者均接受过既往放疗和化疗。
- 共记录39例不良事件,最常见为疲乏(16%)和便秘(10%);4例(8%)发生3-4级不良事件。
- 36例(72%)患者在2个月评估时达疾病稳定,中位疾病稳定持续时间4.3个月(贝伐珠单抗初治者5.1个月,贝伐珠单抗难治者3.8个月)。
- 中位无进展生存期4.3个月(95%CI 3.5-5.3),中位总生存期6.5个月(95%CI 6.0-8.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with recurrent high-grade gliomas (HGG) have limited treatment options. HGG utilize the PD-1 pathway to evade immune responses. Checkpoint inhibitors have demonstrated safety and clinical activity in patients with recurrent glioblastoma. We explored the efficacy of nivolumab in recurrent HGG with a primary objective of progression free survival (PFS) and overall survival (OS). METHODS: We retrospectively analyzed HGG patients treated with nivolumab in our institution. We included patients with advanced HGG who received nivolumab at their oncologist's decision. Patients received nivolumab 3 mg/kg every 2 weeks until confirmed progression, intolerable toxicity, death, or physician decision. Radiographic assessments were performed every 8 weeks. RESULTS: Between April 2015 and October 2017, 50 HGG patients received nivolumab. 43 patients received nivolumab with bevacizumab. 44 patients were bevacizumab refractory and 7 patients received nivolumab monotherapy. All had received prior radiation and chemotherapy. 39 adverse events (AEs) were noted [most commonly fatigue (16%) and constipation (10%)]. 4 (8%) patients experienced grade 3-4 AEs. 36 (72%) patients experienced stable disease (SD) at the 2-month assessment. Median duration of SD was 4.3 months (5.1 months in the bevacizumab naïve, 3.8 months in the bevacizumab refractory). Median PFS was 4.3 months (95% CI 3.5-5.3); median OS was 6.5 months (95% CI 6.0-8.8). CONCLUSION: Treatment with nivolumab therapy was associated with a manageable safety profile. In a subset of patients, there was disease stabilization in heavily pre-treated recurrent HGG.
引用
- Mantica M, Pritchard A, Lieberman F, et al. Retrospective study of nivolumab for patients with recurrent high grade gliomas. J Neurooncol. 2018. PMID: 29779086. doi:10.1007/s11060-018-2907-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。